HJ SCIENCE-B

HJ Science (6132.HK) opened higher but reversed sharply in the morning session, surging to HK$47.80 before tumbling to HK$44.10, for a net loss of ~5.2%. The move was driven by the just-released FY26 H1 results: revenue more than doubled to ~HK$1.94 million, but net loss widened 38.8% to HK$73.48 million, with EPS of -HK$0.6997, deepening the loss profile. The stock has been volatile since the IPO stabilization period ended, posting multiple daily swings. At HK$44.10, it sits 46.2% below its 52-week high of HK$82, yet YTD it is still up 25.1%, and it trades above both its MA20 (HK$42.35) and MA60 (HK$41.36). However, turnover remained thin at a turnover rate of 0.03%.

HJ Science-B opened low and rallied in the morning session, closing up 5.28% at HK$49.80, driven by intensified capital speculation after the stabilization period ended, following a series of sharp swings (e.g., gains of 6%-8% alternating with a 9% drop). The stock remains 39.27% below its 52-week high of HK$82.00 but has rebounded 61.79% from its 52-week low of HK$30.78, while trading above both its MA20 (HK$42.065) and MA60 (HK$41.245), with a YTD gain of 41.24%. The company's PB stands at 9.85x, PE at -24.51x, with a market cap of approximately HK$3.67 billion; today's turnover rate was just 0.02% with a turnover of about HK$751,000. However, without the stabilizing manager's support post-period, elevated volatility may persist.

Huajian Future-B (6132.HK) staged a sharp rebound in the morning session, opening at HK$46.00 and surging to HK$48.48, up 5.39% from the prior close of HK$46.00, with intraday volatility exceeding 8.5%. The rally was driven by positive corporate governance signals, including the board convening to review interim results, an extraordinary general meeting, and a proposed rebranding to 'Huajian Future Biotech.' The stock hit a 52-week high of HK$82.00 on debut on June 23, before dropping to a low of HK$30.78 on July 7. Although the current price has rebounded over 57% from the low, it remains 40.88% below the 52-week high and still trades below its 20-day moving average of HK$41.66. However, the company remains loss-making with a P/E of -23.86x and a high P/B of 9.59x, while today's volume of only 30,200 shares and a turnover rate of 0.04% suggest limited momentum.

HJ Science-B opened sharply higher in the morning session, closing at HK$49.1, up 4.6% from the previous close of HK$46.92, with an intraday high of HK$49.5 and a low of HK$46.56, resulting in a 6.3% range. The rally was driven by the company's recent proposal to rebrand as 'HJ Science Biotech' and plans to hold a board meeting to review interim results. The stock has rebounded 59.52% from its YTD low of HK$30.78, yet remains 40.12% below the 52-week high of HK$82, while trading above both the 20-day MA (HK$41.458) and 60-day MA (HK$40.995), indicating short-term momentum. However, the company remains unprofitable with a P/E of -24.16x and a P/B of 9.71x, underscoring persistent valuation concerns.

6132.HK surged in the morning session, closing at HK$45.04, up 4.5% from the previous close of HK$43.10, driven by narrowing losses in the afternoon and capital positioning after the end of the stabilization period. The intraday high reached HK$45.00 (10:34 BJ), still 45.07% below the 52-week high of HK$82.00, but above MA20 (HK$41.04) and MA60 (HK$40.77), with a YTD gain of 27.74%. Recent corporate actions include a board meeting to review interim results and a proposal to rename to HJ Science Biotech, yet the stock has been volatile post-stabilization, previously falling over 9% in a single day. The current P/B is 8.91x, P/E is -22.16x, and total market cap is approximately HK$3.315 billion, with turnover of only HK$1.78 million, indicating low liquidity, though the price remains above the 20-day moving average, suggesting technical support.